Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | Q9HBH1 | 4/20 | 0.34 | |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20849760 | 0.89 | CHRM1 (0.37) | CA2CA1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL20849756 | 0.89 | CHRM1 (0.37) | CA2CA1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL19483440 | 0.82 | CPB2 (0.38) | — | |
| SCHEMBL22861972 | 0.81 | CA2 (0.39) | CA2MAPK1CA1SLC1A2SLC1A1 | |
| SCHEMBL18594710 | 0.79 | CA2 (0.31) | CA2MAPK1CA1SLC1A2SLC1A1 | |
| SCHEMBL26837413 | 0.78 | — | — | |
| SCHEMBL26897082 | 0.76 | ALOX15 (0.34) | — | |
| SCHEMBL20849992 | 0.76 | — | — | |
| SCHEMBL26153445 | 0.74 | GRIK1 (0.33) | CA2SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL20849759 | 0.73 | AAK1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092808-A1 | SYNTHESIS AND COMPOSITION OF RAPAFUCIN LIBRARIES | THE JOHNS HOPKINS UNIVERSITY | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092808-A1 | SYNTHESIS AND COMPOSITION OF RAPAFUCIN LIBRARIES | MTOR, COASY, RICTOR | CA2 4782/4885MAPK1 2793/4885CA1 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.